Author: admin

LONDON, Feb. 2, 2026 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that its subsidiary, Camelot Finance S.A., has redeemed the remaining $100 million aggregate principal amount of its 4.50% senior secured notes due 2026, originally issued on October 31, 2019 (the “2026 Notes”).

The 2026 Notes were redeemed on January 30, 2026 (the “Redemption Date”) at a cash redemption price equal to 100% of the remaining principal amount, or $100 million, plus accrued and unpaid interest through the Redemption Date. With this transaction, the 2026 Notes have now been fully redeemed.

This redemption was funded with cash on hand and is consistent with Clarivate’s ongoing efforts to simplify its capital structure, reduce debt, and enhance financial flexibility.

As part of its broader capital allocation strategy, Clarivate also announced that it repurchased approximately 21 million ordinary shares for $75 million during the fourth quarter of 2025. For the full year of 2025, Clarivate repurchased approximately 56 million ordinary shares for $225 million. These share repurchases reflect Clarivate’s disciplined approach to returning capital to shareholders while investing for long‑term growth.

“The full redemption of our remaining 2026 Notes, combined with our share repurchase activity throughout 2025, reflects the continued execution of our disciplined capital allocation strategy,” said Jonathan Collins, Executive Vice President and Chief Financial Officer. “We remain focused on strengthening our balance sheet, enhancing financial flexibility, and driving long‑term value creation for our shareholders.”

Forward-Looking Statements
This release includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor provisions” of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts, and include statements regarding our intentions, beliefs, or current expectations concerning, among other things, anticipated cost savings, results of operations, financial condition, liquidity, prospects, growth, strategies, and the markets in which we operate. Such forward-looking statements are based on available current market material and management’s expectations, beliefs, and forecasts concerning future events impacting us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in Item 1A. Risk Factors in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Please consult our public filings with the SEC, which are also available on our website at www.clarivate.com.

About Clarivate 
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.

SOURCE Clarivate Plc

Multi-country recalls of several infant formula products are ongoing following the detection of cereulide – a toxin produced by the bacterium Bacillus cereus. The European Commission asked EFSA to deliver urgent scientific advice to support risk management The management of risks which have been identified by risk assessment. It includes the planning, implementation and evaluation of any resulting actions taken to protect consumers, animals and the environment decisions across the EU.

In its rapid risk assessment, EFSA’s scientists established an acute reference dose (ARfD) for cereulide in infants and established cereulide concentrations in infant formula of potential safety concern. This advice is intended to help EU risk managers determine when products should be withdrawn from the market as a precautionary public health measure.

Key scientific findings

A health-based guidance value Guidance on safe consumption of substances that takes into account current safety data, uncertainties in these data, and the likely duration of consumption for infants

EFSA’s scientists proposed an ARfD An acute reference dose (ARfD) is the estimate of the amount of a substance in food – normally expressed on a body-weight basis (mg/kg or μg/kg of body weight) – that can be ingested in a period of 24 hours or less without appreciable health risk to the consumer. of 0.014 μg/kg body weight for cereulide in infants. Emesis (vomiting) is the critical acute adverse effect A change in the health, growth, behaviour or development of an organism that impairs its ability to develop or survive used to set the ARfD, which was derived using benchmark dose The minimum dose of a substance that produces a clear, low level health risk, usually in the range of a 1-10% change in a specific toxic effect such as cancer induction modelling. Because very young infants (below 16 weeks) metabolise substances differently from adults, EFSA took a cautious approach and added an extra safety factor when setting an ARfD.

Consumption values used to estimate acute exposure A one-off or very short term exposure to a substance, usually less than 24 hours

For infant formula, EFSA confirmed that a value of 260 mL per kilogram of body weight remains appropriate for estimating short-term (24-hour) exposure Concentration or amount of a particular substance that is taken in by an individual, population or ecosystem in a specific frequency over a certain amount of time. For follow-on formula Breast milk substitute aimed at infants who have commenced complementary feeding (i.e. the introduction of solid foods at or around 6 months of age) – which is generally not consumed by infants younger than 16 weeks – EFSA confirmed a value of 140 mL per kilogram of body weight for the same purpose. These values are based on the higher end of what infants typically drink, so that the assessment stays conservative.

Concentrations that may lead to exceedance of the ARfD

By comparing the ARfD with these high consumption values, EFSA concluded that cereulide concentrations in reconstituted (liquid) infant formula above:

• 0.054 μg/L or infant formula, and
• 0.1 μg/L for follow-on formula,

may lead to safe levels being exceeded.

Public health advice and recommendations

Recalled products should not be given to infants or young children. Consumers are advised to follow the instructions and guidance issued by national food safety authorities.

For infants who develop vomiting or diarrhoea after consuming infant formula included in the recall, the European Centre for Disease Prevention and Control (ECDC) recommends seeking medical advice from a healthcare professional, such as a paediatrician, or, if the symptoms are severe (e.g., dehydration or persistent vomiting), at an emergency department. Gastrointestinal symptoms in infants can rapidly lead to complications, regardless of the underlying cause.

More information